Gliomas lacking detectable MGMT activity (i.e., Mer- status) are not more responsive to alkylator therapy

Silber, J.R., Blank, A., Bobola, M.S., Ghatan, S., Kolstoe, D.D. and Berger, M.S. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin. Cancer Res. 5: 807-814, 1999

Proportion of progression-free patients as a function of time after starting alkylating agent therapy. A, results for 62 gliomas, 20 Mer- and 42 Mer+. B, results for 19 anaplastic astrocytomas and 24 glioblastomas, 15 Mer- and 28 Mer+. These findings suggest that MGMT is not the primary determinant of clinical response to alkylating agents in gliomas.